Kijk op onze speciale pagina met aanbestedingen van medisch materiaal in verband met de coronacrisis.
United Kingdom-Oxford: Medical equipments, pharmaceuticals and personal care products
Prior information notice
This notice is for prior information only
Section I: Contracting authority
Main address: http://www.ouh.nhs.uk
Address of the buyer profile: http://www.ouh.nhs.uk
Section II: Object
Provisional Aseptic Services for Oxford University Hospitals NHS Foundation Trust
The aseptic service provider will be required to prepare and deliver drugs and associated services within a sterile environment by microbiologists, pharmacists and pharmacy technicians who make up the bespoke patient doses from base drugs.
The supplier will be expected to provide the service from a fully staffed MHRA compliant manufacturing facility, within 5 km of the OX3 9DU postcode.
OUH may purchase the drugs directly, that will be ‘handled’ by the supplier, or instruct the supplier to purchase them on the Trusts behalf to then be rebated on a monthly basis to deliver the compound service.
The supplier will be required to manufacture named patient supply and batch supplies of Parenteral Nutrition, Biologicals and Chemotherapy, Essentially, the supplier will receive raw materials (un-compounded drugs) and process them into tangible products as per the Trusts requirements.
The supplier will be required to manufacture named patient supply and batch supplies of Parenteral Nutrition, Biologicals and Chemotherapy, Essentially, the supplier will receive raw materials (un-compounded drugs) and process them into tangible products as per the Trusts requirements, with the current levels detailed below:
This will be for Adults, Paediatric and Neonatal patients.
Current annual volume of work is:
— 3 471 Adult standard TPN bags,
— 517 Adult standard TPN bags with tailored additions,
— 2 060 Adult bespoke TPN bags,
— 750 Paediatric TPN Bags as a mixture of batches of standard formulations and tailor made bags named for pts,
— 4 584 Neonatal TPN bags as a mixture of standard bags of the shelf, batches of standard formulations and tailored bags named for pts,
— 30 602 named patient cancer chemotherapeutic doses,
— 4 144 named patient mono-clonal antibodies,
— 1 788 named patient biological.
Section IV: Procedure
Section VI: Complementary information